ТАРАКАРАМАН Каннан (US),ВИСВАНАТАН Картик (US),РАМАН Рахул (US),САСИСЕКХАРАН Рам (US)
申请号：
RU2013114424/10
公开号：
RU2013114424A
申请日:
2011.10.04
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical composition comprising: a binding agent comprising a polypeptide of hemagglutinin H5, amiokislotnuyu which has a sequence that differs from the sequence of the hemagglutinin H5 reference polypeptide by one or more residues selected from the group consisting of residues at positions 130, 131, 132, 133 , 135, 137, 155, 188, 192, 193, 221, 226, 227, 228 and their kombinatsiy.2. A pharmaceutical composition according to claim 1, characterized in that said binding agent competes for interaction glycan hemagglutinin polypeptide between an umbrella topology glycan with and gemagglyutinina.3 polypeptide. A pharmaceutical composition according to claim 1, characterized in that said polypeptide H5 hemagglutinin has a length in the range 19-55 aminokislot.4. A pharmaceutical composition according to claim 1, characterized in that said hemagglutinin H5 polypeptide has an amino acid sequence comprising a portion that has a length of at least 19 amino acids and exhibits at least 95% overall sequence identity with the corresponding part of hemagglutinin polypeptide selected from the group consisting of SEQ ID NOS: 50, 51, 53, 54 or 55.5. A pharmaceutical composition according to claim 1, characterized in that said hemagglutinin H5 polypeptide has an amino acid sequence which shows at least 95% identity with a reference hemagglutinin H5, selected from the group consisting of SEQ ID NOS: 50, 51, 53, 54 or 55, in the region corresponding to amino acids 1-55, but differs from said reference hemagglutinin one or more radicals selected from the group consisting of residues at positions 130, 192, 193 and their kombinatsiy.6. pharmaceuticals to1. Фармацевтическая композиция, содержащая:связывающий агент, включающий полипептид гемагглютинина H5, который имеет амиокислотную последовательность, которая отличается от последовательности эталонного полипептида гемагглютинина H5 по одному или более остаткам, выбранным из группы, состоящей из остатков в положениях 130, 131, 13
